E-DRUG: U.S. FDA issues warning for new heart drug

e-drug
1

E-DRUG: U.S. FDA issues warning for new heart drug (2)
------------------------------------------------------

My understanding is that Posicor vasodilation (primarily
arterial), slight negative chronotropism, but no negative inotropism and
is thus different that Carvedilol, Verapamil, or Diltiazem in this last
property. It is approved for hypertension and angina, but it seems like
an ideal drug for CHF - especially if there is combined diastolic and
systolic dysfunction. Our detail man says it is being
studied in CHF - does anyone have any experience in using Posicor for CHF?]

--
Robert Marshall, MD
Kirkpatrick Clinic
Longview, WA
USA
Email: marshalr@ohsu.EDU

--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.